Drugs / VANGATALCITE
VANGATALCITE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06248086 | Sep → Dec 2024 | neoplasm of mature B-cells | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VANGATALCITE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108826 ↗ |
| Known as | MA-20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06248086 ↗ |
| Known as | Vangatalcita | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108826 ↗ |
| Modality | Protein / enzyme biologic | “MA-20 is a protein” NCT06248086 ↗ |